Sandoz Reveals Bio100 Ambition at Capital Markets Day

On September 8, 2026, Sandoz Group AG hosted its Capital Markets Day in Basel, focusing on its Bio100 strategy. The company aims to expand its biosimilar portfolio from 13 to over 100 by 2040, enhancing its long-term growth potential. Sandoz plans to increase its coverage of biosimilar loss of exclusivity value to around 80% by 2035 from the current 50%.

The mid-term strategy for 2025-2030 targets a mid-to-high single-digit growth in net sales and aims for a core EBITDA margin of 25-27% by 2030. By 2035, Sandoz aspires to more than double net sales and achieve above 30% core EBITDA margin through the Bio100 initiative. Sandoz's leadership highlights their commitment to providing affordable medicines and creating value for shareholders.

The event included live webcasting, with key speakers like CEO Richard Saynor discussing Sandoz's ambitious pipeline for biosimilars. The company will offer a site visit in Slovenia later this year to showcase its biosimilar development hub.